420 related articles for article (PubMed ID: 26095772)
21. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
22. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
Elife; 2021 Jun; 10():. PubMed ID: 34170818
[TBL] [Abstract][Full Text] [Related]
23. Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development.
Matheus F; Rusha E; Rehimi R; Molitor L; Pertek A; Modic M; Feederle R; Flatley A; Kremmer E; Geerlof A; Rishko V; Rada-Iglesias A; Drukker M
Stem Cell Reports; 2019 May; 12(5):861-868. PubMed ID: 31006630
[TBL] [Abstract][Full Text] [Related]
24. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
[TBL] [Abstract][Full Text] [Related]
25. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
Fujino T; Goyama S; Sugiura Y; Inoue D; Asada S; Yamasaki S; Matsumoto A; Yamaguchi K; Isobe Y; Tsuchiya A; Shikata S; Sato N; Morinaga H; Fukuyama T; Tanaka Y; Fukushima T; Takeda R; Yamamoto K; Honda H; Nishimura EK; Furukawa Y; Shibata T; Abdel-Wahab O; Suematsu M; Kitamura T
Nat Commun; 2021 Mar; 12(1):1826. PubMed ID: 33758188
[TBL] [Abstract][Full Text] [Related]
26. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y; Yang H; Chen S; Zhang P; Li R; Nimer SD; Harbour JW; Xu M; Yang FC
Leukemia; 2018 Aug; 32(8):1834-1837. PubMed ID: 29743720
[No Abstract] [Full Text] [Related]
27. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
28. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
[TBL] [Abstract][Full Text] [Related]
29. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.
Russell B; Johnston JJ; Biesecker LG; Kramer N; Pickart A; Rhead W; Tan WH; Brownstein CA; Kate Clarkson L; Dobson A; Rosenberg AZ; Vergano SA; Helm BM; Harrison RE; Graham JM
Am J Med Genet A; 2015 Sep; 167A(9):2122-31. PubMed ID: 25921057
[TBL] [Abstract][Full Text] [Related]
30. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
31. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation.
Campagne A; Lee MK; Zielinski D; Michaud A; Le Corre S; Dingli F; Chen H; Shahidian LZ; Vassilev I; Servant N; Loew D; Pasmant E; Postel-Vinay S; Wassef M; Margueron R
Nat Commun; 2019 Jan; 10(1):348. PubMed ID: 30664650
[TBL] [Abstract][Full Text] [Related]
32. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
33. Regulation of B Lymphocyte Development by Histone H2A Deubiquitinase BAP1.
Lin YH; Liang Y; Wang H; Tung LT; Förster M; Subramani PG; Di Noia JM; Clare S; Langlais D; Nijnik A
Front Immunol; 2021; 12():626418. PubMed ID: 33912157
[TBL] [Abstract][Full Text] [Related]
34. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor H; Meiners MJ; Cheek MA; Rice W; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36865140
[TBL] [Abstract][Full Text] [Related]
35. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
[TBL] [Abstract][Full Text] [Related]
36. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
[TBL] [Abstract][Full Text] [Related]
37. Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
[TBL] [Abstract][Full Text] [Related]
38. Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.
Urreizti R; Roca-Ayats N; Trepat J; Garcia-Garcia F; Aleman A; Orteschi D; Marangi G; Neri G; Opitz JM; Dopazo J; Cormand B; Vilageliu L; Balcells S; Grinberg D
Am J Med Genet A; 2016 Jan; 170A(1):24-31. PubMed ID: 26768331
[TBL] [Abstract][Full Text] [Related]
39. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
[TBL] [Abstract][Full Text] [Related]
40. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
